Takeda reports positive Phase 3 data for psoriasis drug zasocitinib, beating placebo and Otezla, with rapid PASI responses ...
Discover why Day One Biopharmaceuticals, Inc. is surging with Ojemda's growth, strategic deals, and key 2026 catalysts. Click ...
Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...
Amgen (AMGN) just picked up a meaningful FDA win, with UPLIZNA cleared for a specific subset of adults with generalized ...
Zacks Investment Research on MSN
Investors heavily search Amgen Inc. (AMGN): Here is what you need to know
Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...
Chip Stocks with Growing Dividends. On December 12, Morgan Stanley cut its price target for Amgen Inc. (NASDAQ:AMGN) from ...
Verizon's payout is higher than you'd receive from a high-yield savings account or government bonds, so it's a smart place to ...
As of Tuesday, December 16, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has dipped by 8.47%, which has investors ...
Investor's Business Daily on MSN
Amgen sees RS rating improve to 71
In a welcome move, Amgen AMGN saw its Relative Strength Rating improve from 66 to 71 on Monday. Please watch the video at Investors.com - How To Trade Options: Choosing The Right Strategy For Best ...
BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...
Amgen secures FDA approval for Uplinza in generalized myasthenia gravis, giving antibody-positive adults a targeted treatment option supported by Phase 3 data.
Amgen AMGN announced that the FDA has approved its rare disease drug Uplizna (inebilizumab) for a new indication — generalized myasthenia gravis (gMG). The drug is approved to treat the disease in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback